Apricitabine: Phase IIb/III ongoing

Avexa began the Phase III portion of a double-blind, international Phase IIb/III (AVX-301) trial comparing 800 and 1,200 mg of oral apricitabine given twice daily vs. 150 mg of oral lamivudine ( 3TC) ...